Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial

The Lancet Oncology

Volumn 14, Issue 3, 2013, Pages 257-264

  Haddad, Robert ^a,b   O'Neill, Anne ^b   Rabinowits, Guilherme ^b   Tishler, Roy ^b   Khuri, Fadlo ^c   Adkins, Douglas ^d   Clark, Joseph ^e   Sarlis, Nicholas ^f   Lorch, Jochen ^b   Beitler, Jonathan J ^c   Limaye, Sewanti ^b   Riley, Sarah ^b   Posner, Marshall ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f SANOFI   (France)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OROPHARYNX CANCER; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TAXOIDS;

EID: 84875267472     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70011-1     Document Type: Article

References (23)

1. Haddad RI, Shin DM Recent advances in head and neck cancer. N Engl J Med 2008, 359:1143-1154.
2. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
3. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 2005, 23:3008-3015.
4. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21:92-98.
5. Pignon JP, Bourhis J, Domenge C, Designe L Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 355:949-955. on behalf of the MACH-NC Collaborative Group.
6. Pignon JP, le Maitre A, Maillard E, Bourhis J Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
8. Ang K, Zhang E, Rosenthal D, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 5500.
9. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715.
10. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704.
11. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009, 101:498-506.
12. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350:1945-1952.
13. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937-1944.
14. Forastiere A, Zhang Q, Weber R, et al. Long term results of Intergroup RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2012, published online Nov 26. 10.1200/JCO.2012.43.6097.
15. Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010, 21:1515-1522.
16. Hitt R, Grau J, Lopez-Pousa A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). Proc Am Soc Clin Oncol 2009, 27(suppl). abstr 15s.
17. Cohen E, Karrison T, Kocherginsky M, et al. DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 5500.
18. Tishler RB, Posner MR, Norris CM, et al. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2006, 65:1036-1044.
19. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
20. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000, 92:709-720.
21. Mork J, Lie K, Glattre E, et al. Human Papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001, 344:1125-1131.
22. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28:4142-4148.
23. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011, 22:1071-1077.